Form 4: Amylyx Pharmaceuticals Director Acquires Stock Options

Paul R. Fonteyne, a Director at Amylyx Pharmaceuticals, acquired stock options for 24,372 shares.

Summary

• Paul R. Fonteyne, a Director at Amylyx Pharmaceuticals, Inc. (AMLX), acquired stock options on June 4, 2026.
• The options grant the right to purchase 24,372 shares of common stock at an exercise price of $14.31 per share.
• These options are set to expire on June 3, 2036.
• The shares subject to the option will vest in full on the earlier of June 4, 2027, or the date of the next annual meeting, provided Fonteyne remains in continuous service to the Issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard grant of stock options to a director, indicating alignment of interests but not necessarily a significant change in company performance.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of options at a specific exercise price indicates a potential for future value appreciation.

Risks

• The vesting schedule for the options is contingent on the Reporting Person's continuous service, meaning any departure before the vesting date could result in forfeiture.
• The value of the options is subject to market fluctuations and the company's performance.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's future performance, as the value of these options is tied to the stock price.

Industry Context

StockSavvy.ai notes that insider option grants, particularly to directors, are common in the biotechnology and pharmaceutical sectors as a means of aligning executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive alignment of interests, potentially leading to increased focus on long-term value creation.
• Employees: While not directly impacted, such grants can contribute to a culture of performance-driven incentives within the company.
• Management: Reinforces the use of equity-based compensation to retain and motivate key personnel.

Next Steps

• Paul R. Fonteyne will continue to provide service to Amylyx Pharmaceuticals, Inc.
• The stock options will vest according to the schedule outlined in the filing.
• The company's stock performance will determine the ultimate value of the acquired options.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Form 4, Stock Options, Insider Trading, Director, Beneficial Ownership, Securities Exchange Act